* Mink Therapeutics Inc INKT.OQ reported a quarterly
adjusted
loss of 23 cents per share for the quarter ended in December.
The mean expectation of four analysts for the quarter was for a
loss of 21 cents per share.
* Reported revenue was zero; analysts expected zero.
* Mink Therapeutics Inc's reported EPS for the quarter was a
loss
of 23 cents.
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* Mink Therapeutics Inc shares had fallen by 20.3% this
quarter.
* The company reported a quarterly loss of $7.77 million.
* Wall Street's median 12-month price target for Mink
Therapeutics
Inc is $7.00
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data
March 21 at 02:11 p.m. UTC. All figures in US dollars unless
otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2022 -0.21 -0.23 Missed
Sep. 30 2022 -0.23 -0.19 Beat
Jun. 30 2022 -0.24 -0.18 Beat
Mar. 31 2022 -0.21 -0.23 Missed